B‐Type Natriuretic Peptide: The Level and the Drug—Partners in the Diagnosis and Management of Congestive Heart Failure
Key result
B-type natriuretic peptide serves as an objective marker for the diagnosis and prognosis of heart failure, and its recombinant form, nesiritide, offers a therapeutic approach for decompensated cases.
Population
Patients with congestive heart failure or acute coronary syndromes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide heart failure assessment now; leaves open nesiritide's net benefit pending randomized trials.
Key Points
- To review clinical evidence on the diagnostic and prognostic utility of endogenous B-type natriuretic peptide alongside the therapeutic role of recombinant B-type natriuretic peptide in decompensated heart failure.
- Synthesized published literature assessing plasma B-type natriuretic peptide concentrations across acute coronary syndromes and congestive heart failure.
- Evaluated pharmacologic mechanisms and therapeutic administration of recombinant B-type natriuretic peptide (nesiritide) in decompensated states.
- B-type natriuretic peptide provides an objective biomarker that overcomes the diagnostic ambiguity of nonspecific heart failure signs and symptoms.
- Endogenous peptide release functions as a compensatory distress signal that often fails to maintain vascular balance, supporting exogenous peptide administration to restore neurohormonal homeostasis.
Structured PICO
P
Population
Patients with congestive heart failure or acute coronary syndromes
I
Intervention
B-type natriuretic peptide (as a diagnostic marker) and recombinant B-type natriuretic peptide / nesiritide (as a therapeutic agent)
B-type natriuretic peptide serves as both an objective biomarker for diagnosing and prognosticating heart failure, and as a therapeutic agent (nesiritide) for decompensated heart failure.
Cite This Study
Bhalla et al. (2004) conducted a review in Congestive heart failure. B-type natriuretic peptide (BNP) and nesiritide was evaluated. B-type natriuretic peptide serves as an objective marker for the diagnosis and prognosis of heart failure, and its recombinant form, nesiritide, offers a therapeutic approach for decompensated cases.